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Abstract
Summary: Individual tumor genomes pose a major challenge for clinical interpretation due to their
unique sets of acquired mutations. There is a general scarcity of tools that can (i) systematically
interrogate cancer genomes in the context of diagnostic, prognostic, and therapeutic biomarkers, (ii)
prioritize and highlight the most important findings and (iii) present the results in a format accessible
to clinical experts. We have developed a stand-alone, open-source software package for somatic vari-
ant annotation that integrates a comprehensive set of knowledge resources related to tumor biology
and therapeutic biomarkers, both at the gene and variant level. Our application generates a tiered re-
port that will aid the interpretation of individual cancer genomes in a clinical setting.
Availability and implementation: The software is implemented in Python/R, and is freely available
through Docker technology. Documentation, example reports, and installation instructions are ac-
cessible via the project GitHub page: https://github.com/sigven/pcgr.
Contact: sigven@ifi.uio.no
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
A range of different tools have been developed for functional annota-
tion of genomic variants (McLaren et al., 2016; Ramos et al., 2015;
Wang et al., 2010). Although some have a specific focus on the oncol-
ogy domain (e.g. Oncotator), they are all largely targeted towards the
research community. Existing solutions offer limited support for sum-
maries and reports at the level of individual cancer genomes, particu-
larly when it comes to clinical relevance. Moreover, the degree of
quality control and update frequency of annotation resources vary
considerably. Recently, we have seen significant development of data-
bases that harvest reports from the scientific literature about cancer
genome variants and their particular relationships to tumorigenesis,
druggability and clinical outcomes. These include the Database of
Curated Mutations (DoCM), The Drug Gene Interaction Database
(DGIdb) and most importantly the community-driven database of
Clinical Interpretations of Variants in Cancer (CIViC) (Ainscough
et al., 2016; Griffith et al., 2017; Wagner et al., 2016). Other re-
sources covering known cancer mutation hotspots, mutational signa-
tures and predicted driver mutations have also emerged, which
collectively indicate potential underlying mechanisms of tumor devel-
opment and relevance for different treatment regimes (Chang et al.,
2016; Gonzalez-Perez et al., 2013; Secrier et al., 2016).
We have developed the Personal Cancer Genome Reporter
(PCGR), a software package for the generation of clinically inter-
pretable reports of individual cancer genomes. The software extends
basic variant annotations from Variant Effect Predictor (VEP) with
oncology-relevant annotations retrieved flexibly with vcfanno
(Pedersen et al., 2016), and produces interactive HTML reports that
are intended for clinical translation.
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2 PCGR workflow
The pipeline for generation of personal cancer genome reports com-
prises four major steps: (i) basic variant consequence annotation
using VEP, (ii) allele-specific annotation for precision oncology
using vcfanno, (iii) functional and cancer-focused gene annotation
and (iv) prediction of MSI status, estimation of mutational signature
contributions, summary, prioritization and reporting with the R lan-
guage and R markdown templates (Supplementary Fig. S1). All soft-
ware components are integrated and provided by means of the
Docker technology, implying that all underlying dependencies are
packaged into a standardized software container. The Docker solu-
tion was chosen to offer individual labs a simple installation of
PCGR in their in-house workflow for high-throughput analysis of
tumor genomes. The application comes with an annotation data
bundle, which we plan to update on a quarterly basis. The human
genome assembly GRCh37 is currently supported.
The PCGR workflow accepts two types of input files: (i) a single-
sample VCF file encoding the genomic coordinates of somatic
SNVs/Indels and (ii) a basic somatic copy number segment file that
encodes chromosomal segment locations and their log-2 ratios (spe-
cific requirements are given in the GitHub documentation).
For SNVs and Indels encoded in a VCF file, VEP is utilized to de-
termine variant consequence information. For the sake of simplicity
and ease of use, the VEP annotation is run with a fixed set of param-
eters that includes all gene cross-references, protein domain annota-
tions, and overlap with regulatory regions, using GENCODE as the
underlying gene transcript model. All transcript-dependent conse-
quences per variant are retained in the VEP-annotated VCF file, and
the consequence block of highest functional relevance (as provided
by VEP’s –flag_pick option) is flagged for further downstream ana-
lysis. Next, vcfanno is applied on multiple variant databases in par-
allel in order to enrich each somatic call with allele-specific
annotations that are directly or indirectly relevant for clinical inter-
pretation. These allele-specific annotations include, (i) pathogenicity
predictions for splice-site and missense variants by multiple algo-
rithms, (ii) overlap with known mutational cancer hotspots and pre-
viously predicted driver mutations, (iii) tissue/tumor type frequency
in case of previously detected somatic variants, (iv) known disease/
cancer associations and (v) clinical evidence items of relevance for
diagnosis, prognosis, predisposition, or drug sensitivity/resistance.
In the third step of the workflow, gene-level annotations are
aggregated. Known proto-oncogenes and tumor suppressors are
marked, as are other genes implicated (either by prediction or cur-
ation) in cancer (Pi~nero et al., 2017). Antineoplastic agents and their
molecular targets are also annotated. Each gene is finally assigned a
score that reflects its relative strength of association to cancer in the
biomedical literature, enabling ranking of novel variants according
to functional relevance (Rocco et al., 2017). The annotation of copy
number aberrations is limited to this third step, in which gene tran-
scripts that intersect gained or depleted segments are identified, and
clinical and etiologic cancer associations are retrieved.
The final and fourth step of the PCGR workflow summarises
and prioritizes the annotated variants in a structured and interactive
report, adopting recently proposed recommendations (Dienstmann
et al., 2014; Ritter et al., 2016). Specifically, a tiered report is con-
structed, starting from actionable markers in Tier 1, toward aberra-
tions relevant for tumorigenesis in Tier 2 and 3, and ending with
variants of unknown functional relevance in Tier 4 and 5. In add-
ition to the tier structure, mutated genes in Tier 3-5 are prioritized
by means of the above-mentioned literature-derived score for onco-
genic potential, which draws attention to the most relevant findings.
Finally, the report offers optional prediction of microsatellite in-
stability, in addition to estimates of known mutational signatures
present in the tumor, and their associated underlying etiologies
(Rosenthal et al., 2016). An example report for a breast cancer gen-
ome is found within the Supplementary Material.
3 Discussion
We have utilized the Docker technology to develop a report engine
for clinical interpretation of cancer genomes. The tool has a particu-
lar focus on actionable, coding variants, i.e. variants found through
exome sequencing. The Cancer Genome Interpreter (CGI, https://
cancergenomeinterpreter.org) can identify tumor alterations that are
therapeutically actionable, similar to the functionality that is imple-
mented in PCGR. CGI is a web-based solution, while PCGR is a
stand-alone annotation engine intended for integration in tumor
sequencing pipelines. Moreover, PCGR exploits the total spectrum
of tumor variants to compute additional measures that can inform
precision therapy, i.e. MSI status, mutational signatures, and muta-
tional burden.
Matching biomarker results more stringently to the cancer type
of the query will be prioritized in future extensions of PCGR.
Furthermore, we foresee that the report can be significantly strength-
ened through the addition of other molecular profiling datasets, such
as gene expression. Expression will not only add an important layer
on top of results found at the DNA level, it can also add significant
value towards assessment of therapeutic potential by other analyses,
such as inference of cell type composition in the tumor tissue, and in
silico predictions of drug response.
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